Using Model‐Based “Learn and Confirm” to Reveal the Pharmacokinetics‐Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE‐001 Trial

por Elassaiss‐Schaap, J, Rossenu, S, Lindauer, A, Kang, SP, de Greef, R, Sachs, JR, de Alwis, DP
Publicado 2016

Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose‐Range Selection of the Anti–PD‐1 Antibody Pembrolizumab

por Lindauer, A, Valiathan, CR, Mehta, K, Sriram, V, de Greef, R, Elassaiss‐Schaap, J, de Alwis, DP
Publicado 2016

Model‐Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti–PD‐1 Monoclonal Antibody in Advanced Solid Tumors

por Ahamadi, M, Freshwater, T, Prohn, M, Li, CH, de Alwis, DP, de Greef, R, Elassaiss‐Schaap, J, Kondic, A, Stone, JA
Publicado 2016

Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma

por de Greef, R, Elassaiss‐Schaap, J, Chatterjee, M, Turner, DC, Ahamadi, M, Forman, M, Cutler, D, de Alwis, DP, Kondic, A, Stone, J
Publicado 2016

Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab‐Treated Advanced Melanoma

por Chatterjee, MS, Elassaiss‐Schaap, J, Lindauer, A, Turner, DC, Sostelly, A, Freshwater, T, Mayawala, K, Ahamadi, M, Stone, JA, de Greef, R, Kondic, AG, de Alwis, DP
Publicado 2016